Camrelizumab Plus Stereotactic Body Radiotherapy vs Camrelizumab Alone For Oligometastatic Nasopharyngeal Carcinoma

NCT04944914 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

188

Enrollment

OTHER

Sponsor class

Conditions

Nasopharyngeal Carcinoma

Interventions

DRUG: camrelizumab
RADIATION: stereotactic body radiotherapy

Sponsor

Sun Yat-sen University

Collaborators

[object Object]
[object Object]
[object Object]